Dergiler / European Journal of Rheumatology / 2018 / Cilt: 5 - Sayı: 2

Serum sCTLA-4 levels and clinical manifestations in ankylosing spondylitis patients

Sayfa
115–117
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The data were analyzed by using relevant sta-tistical methods.Results: In comparison with RA patients and controls, patients with AS showed high sCTLA-4 lev-els (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: T cell abnormal activation is thought to have a main role in the etiology of ankylosingspondylitis (AS).
📊
Temel Bulgular & Veri:While cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) is suppressing the im-mune system, in previous studies serum soluble CTLA-4 (sCTLA-4) was detected at high amounts inautoimmune disorders.
💡
Sonuç & Katkı:The data were analyzed by using relevant sta-tistical methods.Results: In comparison with RA patients and controls, patients with AS showed high sCTLA-4 lev-els (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: T cell abnormal activation is thought to have a main role in the etiology of ankylosingspondylitis (AS). While cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) is suppressing the im-mune system, in previous studies serum soluble CTLA-4 (sCTLA-4) was detected at high amounts inautoimmune disorders. We sought to evaluate the association between soluble CTLA-4 in serum anddisease activity in AS patients.Methods: Thirty-eight patients with AS, 28 rheumatoid arthritis (RA) patients, and 27 disease-free con-trols were enrolled to the study. The levels of sCTLA-4 were determined for each participant using anenzyme-linked immunosorbent assay. The erythrocyte sedimentation rate (ESR), C-reactive peptide,and demographic characteristics were documented. The data were analyzed by using relevant sta-tistical methods.Results: In comparison with RA patients and controls, patients with AS showed high sCTLA-4 lev-els (p

🔖

Bu Makaleye Atıf Yap

AYDIN, N., ŞENTÜRK, T., SARGIN, G., ÇETİNTEPE, S. P. (2022). Serum sCTLA-4 levels and clinical manifestations in ankylosing spondylitis patients. European Journal of Rheumatology, Cilt: 5 - Sayı: 2, 115–117. https://ajindex.com/articles/511647

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Toussirot E, Saas P, Deschamps M, Pouthier F, Perrot L, Perruche S, et al. Increased production of soluble CTLA-4 in patients with spondylar- thropathies correlates with disease activity. Ar- thritis Res Ther 2009
  2. [CrossRef ] Lee WY, Chang YH, Lo MK, Chang CP, Yang SC, Yang TP, et al. Polymorphisms of cytotoxic T lymphocyte-associated antigen-4 and cytokine genes in Taiwanese patients with ankylosing spondylitis. Tissue Antigens 2010
  3. [CrossRef ] Lenschow DJ, Walunas TL, Bluestone JA. CD28/ B7 system of T cell costimulation. Annu Rev Im- munol 1996
  4. [CrossRef ] Thompson CB, Allison JP. The Emerging Role of CTLA-4 as an Immune Attenuator. Immunity 1997
  5. [CrossRef ] Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, et al. CTLA-4 can func- tion as a negative regulator of T cell activation Immunity 1994
  6. [CrossRef ] Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activa- tion. J Exp Med 1996
  7. [CrossRef ] Luhder F, Chambers C, Allison JP, Benoist C, Mathis D. Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci 2000
  8. 12204-9. [CrossRef ] Chikuma S, Imboden JB, Bluestone JA. Negative Regulation of T Cell Receptor-Lipid Raft Interac- tion by Cytotoxic T Lymphocyte-associated An- tigen 4. J Exp Med 2003
  9. [CrossRef ] Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA. Distinct roles of CTLA-4 and TGF-β in CD4+CD25+ regulatory T cell function. Eur J Immunol 2004
  10. [CrossRef ] Tai X, Cowan M, Feigenbaum L, Singer A. CD28 costimulation of developing thymocytes in- duces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol 2005
  11. [CrossRef ] Oaks MK, Hallett KM. Cutting Edge: A Soluble Form of CTLA-4 in Patients with Autoimmune Thyroid Disease. J Immunol 2000
  12. [CrossRef] Wang XB, Kakoulidou M, Giscombe R, Qiu Q, Huang D, Pirskanen R, et al. Abnormal expression of CTLA-4 by T cells from patients with myasthe- nia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 2002
  13. [CrossRef] Liu MF, Wang CR, Chen PC, Fung LL. Increased Expression of Soluble Cytotoxic T-Lympho- cyte-Associated Antigen-4 Molecule in Patients with Systemic Lupus Erythematosus. Scand J Immunol 2003
  14. [CrossRef ] Ramos M, De Castro JAL. HLA-B27 and the pathogenesis of sp